Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer

Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer

Raloxifene (RLX) is a second-generation selective estrogen receptor modulator approved for the prevention of invasive breast cancer in women. Oral therapy of RLX requires daily intake and is associated with side effects that may lead to low adherence. We developed a weekly transdermal delivery syste...

Full description

Bibliographic Details
Main Authors: Deepal Vora, Amruta Dandekar, Sonalika Bhattaccharjee, Onkar N. Singh, Vivek Agrahari, M. Melissa Peet, Gustavo F. Doncel, Ajay K. Banga
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceutics
Subjects:
raloxifene
breast cancer
in vitro permeation testing
transdermal delivery
transdermal gel
chemical enhancer
Online Access:https://www.mdpi.com/1999-4923/14/3/680

Similar Items

Similar Items